Herceptin is the current standard-of-care therapy, and is used in every line of treatment, primarily as part of a combination regimen. However, it has steadily lost market share following the introduction of trastuzumab biosimilars in 2019. 

Despite initially encountering reimbursement challenges, Perjeta in combination with Herceptin has become the standard of care for both neoadjuvant and first-line treatment of HER2+ breast cancer after demonstrating an overall survival benefit in the Phase III CLEOPATRA and APHINITY studies. Additionally, Roche has launched Phesgo, a subcutaneous fixed-dose formulation of the combination. 

This Datamonitor Healthcare report contains a Disease Analysis module.